AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biohit Oyj

Share Issue/Capital Change Jul 5, 2018

3304_dirs_2018-07-05_4e016153-692f-401c-9429-fedf6d9fd628.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Disclosure 363127

Biohit Oyj - Changes in company's own shares

Biohit Oyj B-shares Subscribed with Stock Options I 2013

Biohit Oyj Stock Exchange Release July 5, 2018 at 09:30 a.m. (EEST)

A total number of 10,054 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 7 February 2018 and 4 June 2018. These shares have been entered into the Trade Register on July 2, 2018, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading begins on NASDAQ Helsinki as of July 3, 2018 together with the existing B-shares.

The share subscription price was EUR 2.2766 per share respectively. The entire subscription price of EUR 22,888.94 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value.

After the subscriptions the number of all Biohit Oyj's shares will rise to 14,899,332 shares and B-shares will rise to 11,923,832 shares.

The share subscription period with stock options I 2013 began on June 1, 2015 and will end May 31, 2019.The option schemes are based on the Biohit Oyj board resolution of June 19, 2013 and the Annual General Meeting authorization of April 13, 2011. The terms and conditions of the option schemes with additional information are available on Biohit Oyj website at www.biohithealthcare.com.

Additional information:

CEO Semi Korpela, Biohit Oyj

tel. +358 9 773 861

[email protected]

www.biohithealthcare.com

Distribution:

NASDAQ Helsinki

Major media

Talk to a Data Expert

Have a question? We'll get back to you promptly.